Exosomal galectin-3 mediated stromal activation and immunosuppression in advanced gastric adenocarcinoma

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,774,998.00 to the Coriell Institute for Medical Research, Inc., a non-profit biomedical research center, to conduct research on exosomal galectin-3 mediated stromal activation and immunosuppression in advanced gastric adenocarcinoma. The award, effective from September 30, 2024 to September 29, 2027, supports the institute's innovative scientific investigations into the cellular mechanisms underlying this form of cancer, with the aim of developing improved diagnostic and treatment approaches. Coriell Institute, with its extensive expertise in areas such as cell line development, genetic research, and biospecimen management, is well-positioned to carry out this critical biomedical research project that could have significant implications for military personnel and the broader public.